This Report features up to a ten-year record of the equity Price history for UCB SA. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.
UCB SA(UCB). The Group's principal activity is to manufacture and market innovative pharmaceutical and biotechnological products. It includes research and drug manufacture for neurological disorders. The Group manufacures medicines for central nervous system disorders, allergies, respiratory diseases, cardiovascular diseases, inflammatory disorders, epilepsy, multiple sclerosis and cancer therapy. The research and development team works on antibody research. Their products include Keppra, Xyzal, Nootropi, Atarax, Lortab, Tussionex and Metadate. The Group operates mainly in Europe, the United States, Asia, Africa, Oceania and Middle East.
Not the Report you are looking for?Click here for more browsing options.
* If a currency is not selected, the report will be delivered in the local currency of the company ** Full access limits users to 500 reports per month
Web site and selected data copyright 2008 The Winthrop Corporation. All rights reserved. Selected data copyright 2008, "Worldscope/Disclosure, L.L.C., a Primark affiliate." All rights reserved.
